India to Peru: Acetaminophen Export Trade Route

To import Acetaminophen formulations into Peru, the following approvals and registrations are mandatory:

The dossier format aligns with the Common Technical Document (CTD) structure. Approval timelines can vary but typically range from 6 to 12 months, depending on the completeness of the submission and DIGEMID's review process. Product registration fees are determined by DIGEMID and may vary based on the product category and complexity.

3. Local Representation: Foreign manufacturers must appoint a local authorized representative in Peru to facilitate communication with DIGEMID and ensure compliance with local regulations.

4. GMP Inspection Requirements: DIGEMID may require GMP inspections of foreign manufacturing facilities, especially if the GMP certificate is not issued by a recognized health authority. Indian manufacturers should be prepared for potential on-site inspections to verify compliance with Peruvian GMP standards.

Indian exporters of Acetaminophen formulations must adhere to the following GMP standards to supply the Peruvian market:

1. GMP Certification: Manufacturing facilities must possess valid GMP certificates issued by recognized health authorities. Peru accepts GMP certifications from internationally recognized bodies, including the World Health Organization (WHO).

These approvals are contingent upon maintaining compliance with GMP standards and successful completion of any required inspections.

3. Recent Inspections and Regulatory Actions: In November 2025, the Drugs Controller General of India (DCGI) mandated that all pharmaceutical companies, including exporters, comply with revised Schedule M requirements, aligning India's GMP standards with global practices. This directive aims to enhance the quality of pharmaceutical products and may impact Indian manufacturers exporting to Peru.

Several regulatory changes between 2024 and 2026 have influenced Indian pharmaceutical exports to Peru:

1. Revised Schedule M Implementation in India: In December 2023, India's Ministry of Health and Family Welfare updated Schedule M of the Drugs Rules, enhancing GMP standards to align with WHO guidelines. Large pharmaceutical companies were required to implement these standards by June 2024, while Micro, Small, and Medium Enterprises (MSMEs) were given until December 2025. This revision aims to improve the quality of pharmaceutical products exported from India, including those destined for Peru.

2. DIGEMID's Enhanced Inspection Protocols: In August 2024, DIGEMID announced stricter inspection protocols for imported pharmaceutical products, emphasizing compliance with GMP standards. This development underscores the importance for Indian exporters to ensure their manufacturing facilities meet both Indian and Peruvian GMP requirements.

3. Mutual Recognition Agreements (MRAs): As of March 2026, there have been no new Mutual Recognition Agreements between India and Peru concerning pharmaceutical GMP certifications. Therefore, Indian manufacturers must continue to provide comprehensive GMP documentation and may be subject to inspections by DIGEMID to verify compliance.

Staying informed about these regulatory developments is crucial for Indian exporters to maintain uninterrupted access to the Peruvian pharmaceutical market.

In 2025, the revenue in Peru's analgesics market, which includes acetaminophen formulations, is projected to reach approximately $167.22 million USD, with an anticipated annual growth rate of 7.45% from 2025 to 2030. This growth is driven by factors such as an aging population, increased healthcare spending, and a rising preference for over-the-counter pain relief medications. The demand for acetaminophen formulations is further supported by its widespread use for pain and fever relief. While specific data on domestic production versus imports is limited, it is noted that domestic manufacturing in Peru remains limited, with local producers accounting for just 13.19% of the total market value in 2016. This indicates a significant reliance on imports to meet the country's demand for acetaminophen formulations.

Peru maintains a 0% MFN import duty rate for HS code 30049069, which encompasses finished pharmaceutical formulations containing acetaminophen. This exemption aligns with Peru's policy to facilitate access to essential medicines by eliminating import tariffs on pharmaceutical products. Additionally, there are no specific anti-dumping duties imposed on these imports. While Peru has engaged in various Free Trade Agreements (FTAs), the import of pharmaceutical products like acetaminophen formulations generally benefits from the existing 0% tariff rate, regardless of the country of origin.

India is a significant supplier of acetaminophen formulations to Peru, accounting for $2.8 million USD in trade value, representing 1.2% of India's total acetaminophen formulation exports. The primary exporters from India include SOFTGEL HEALTHCARE PRIVATE LIMITED and THE MADRAS PHARMACEUTICALS. The main Peruvian importer is BONAPHARM S.A.C. While specific data on other major supplying countries and their market shares is not provided, the limited domestic production in Peru suggests a reliance on imports from multiple countries. India's competitive pricing and established pharmaceutical manufacturing capabilities position it favorably against competitors such as China and European manufacturers. However, detailed comparative pricing data is not available in the provided information.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global generics trade by volume as of February 2026. (zipdo.co) The country's pharmaceutical manufacturing sector boasts an annual capacity exceeding 70 billion dosage units, encompassing a wide range of finished dosage forms such as tablets, capsules, syrups, and injections. This extensive production capability is supported by over 1,000 pharmaceutical companies with active research and development facilities, ensuring continuous innovation and quality improvement. (zipdo.co)

India's cost structure offers significant advantages, with manufacturing costs approximately 30% to 35% lower than those in the United States and Europe. This cost efficiency is primarily due to lower labor expenses, stringent cost-control measures, and the accelerated adoption of digital technologies. Furthermore, India houses the largest number of FDA-approved generic medicine facilities globally, with 752 sites as of 2024, surpassing even the United States. Additionally, the country has 2,050 WHO-GMP certified facilities, underscoring its commitment to maintaining high manufacturing standards.

Specific to acetaminophen formulations, Indian manufacturers like Granules India Limited have established substantial production capacities. Granules India, for instance, has pioneered India's transition from API importer to global supplier, with paracetamol production capacities exceeding 25,000 metric tons annually across three WHO-GMP facilities. This robust infrastructure ensures a reliable supply of high-quality acetaminophen formulations to meet global demand.

In the third quarter of 2025, the global market for paracetamol (acetaminophen) formulations exhibited notable price variations across different regions. In India, the price stood at $2,911 per metric ton, while in China, it was slightly higher at $3,415 per metric ton. European countries reported even higher prices, with Germany at $3,496 per metric ton and France at $3,787 per metric ton. These figures highlight India's competitive pricing advantage in the production of acetaminophen formulations.

Quality perception and regulatory acceptance are critical factors in pharmaceutical procurement. India's pharmaceutical industry has made significant strides in enhancing quality standards, with a 50% reduction in FDA Official Action Indicated (OAI) outcomes over the last decade. As of 2024, India operates 752 FDA-approved generic medicine facilities, the highest globally, surpassing even the United States. This demonstrates a strong commitment to quality and compliance, making Indian acetaminophen formulations highly acceptable in international markets, including Peru.

Supply reliability is another crucial consideration. Indian manufacturers have invested heavily in infrastructure and operations to ensure consistent supply. For instance, Granules India Limited has paracetamol production capacities exceeding 25,000 metric tons annually across three WHO-GMP facilities. Such capacity ensures a steady supply chain, reducing the risk of disruptions.

In contrast, while China is a significant player in the pharmaceutical industry, it has faced challenges related to environmental regulations and production consistency. European manufacturers, although known for high-quality products, often have higher production costs, leading to more expensive formulations. Local manufacturers in Peru may not have the same scale or cost advantages, making Indian imports a more viable option.

The India-Peru supply chain for acetaminophen formulations has demonstrated reliability, supported by India's substantial manufacturing capacity. Indian pharmaceutical companies have expanded their global focus with significant investments in infrastructure and operations. As of 2024, India operates 752 FDA-approved generic medicine facilities and 2,050 WHO-GMP certified facilities, reflecting a strong commitment to quality and compliance.

Packaging and cold chain capabilities are critical for maintaining the integrity of pharmaceutical products during transit. Indian manufacturers have developed robust systems to ensure that finished dosage forms, including acetaminophen formulations, are packaged and transported under optimal conditions. This includes compliance with international standards for packaging materials and temperature-controlled logistics.

Regarding supply disruptions, there have been no significant reports affecting the India-Peru acetaminophen formulation supply chain in recent years. Indian manufacturers have maintained a consistent supply, supported by their extensive production capacities and adherence to regulatory standards. For example, Granules India Limited has paracetamol production capacities exceeding 25,000 metric tons annually across three WHO-GMP facilities, ensuring a steady supply to meet global demand.

Regulatory compliance is a cornerstone of India's pharmaceutical industry. The country has achieved a 50% reduction in FDA Official Action Indicated (OAI) outcomes over the last decade, indicating improved compliance and quality standards. As of 2024, India operates 752 FDA-approved generic medicine facilities, the highest globally, surpassing even the United States. This track record assures buyers of the reliability and quality of Indian pharmaceutical products.

Capacity constraints are minimal, given the scale of production facilities in India. Manufacturers continue to invest in expanding their capacities to meet growing global demand. For instance, Granules India Limited has paracetamol production capacities exceeding 25,000 metric tons annually across three WHO-GMP facilities, ensuring a steady supply to meet global demand. Such expansions further enhance the reliability of the supply chain.

For Peruvian buyers aiming to source acetaminophen formulations from India, the following strategic recommendations are advised:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions. This approach ensures continuity and leverages competitive pricing.

• Understand Minimum Order Quantities (MOQs): Indian suppliers typically have MOQs that vary based on the product and manufacturer. It's essential to negotiate MOQs that align with your demand forecasts to optimize inventory levels.

• Negotiate Favorable Payment Terms: Common payment terms in India-Peru pharmaceutical trade include letters of credit (LC) and advance payments. Establish clear terms that balance cash flow considerations with supplier trust.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory compliance history, production capacity, quality assurance processes, and past performance. Site audits and third-party certifications can provide additional assurance.

• Stay Informed on Regulatory Requirements: Ensure that imported acetaminophen formulations comply with Peruvian regulatory standards. Collaborate with suppliers to obtain necessary documentation and facilitate smooth customs clearance.

By adhering to these recommendations, Peruvian buyers can establish a robust and reliable supply chain for acetaminophen formulations sourced from India.

Cost Estimates and Timeline:

• Audit Visits to India:
• Plan for a minimum of 3-5 days on-site, depending on the facility's size and complexity.
• Estimated costs include auditor fees, travel, accommodation, and daily expenses, totaling approximately $5,000 to $10,000 per audit.

• Ongoing Monitoring:
• Budget for annual audits and periodic remote assessments, with costs varying based on the depth and frequency of evaluations.

By meticulously following this comprehensive supplier qualification process, Peruvian companies can ensure the procurement of high-quality Acetaminophen formulations from reputable Indian manufacturers, thereby safeguarding public health and maintaining regulatory compliance.